CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Brazil

2017-06-09
Price :
Published : Jun-2017
No. of Pages : 199

Brazil has one of the fastest growing pharmaceutical markets in the world. It is driven by an increasing disease burden and high affordability. However, a decrease in foreign investment and increased government promotion of generic drugs are barriers to growth. The value of the market was US$25.3 Billion in 2016, having increased from US$15.4 Billion in 2009 at a Compound Annual Growth Rate (CAGR) of 3.4%. Changing demographics are an important driver for the market, as the increasingly elderly population will lead to an increase in the incidence of chronic and other lifestyle-associated diseases. The growing middle class, who have high purchasing power, is another major driver.

Brazil’s medical device market was valued at US$7.1 Billion in 2009 and US$9.7 Billion in 2016. It is projected to grow at a CAGR of 6.4% from US$10.9 Billion in 2017 to US$14 Billion in 2021. In 2016, In Vitro Diagnostics (IVD) accounted for 11.5% of the medical device market, followed by orthopedic devices (10.8%), diagnostic imaging (10.6%), ophthalmic devices (8.8%) and cardiovascular devices (8.7%).

Most hospitals in Brazil offer primary care services exclusively. In 2016, health expenditure accounted for 8.2% of GDP, having accounted for 8.6% in 2009. Brazilian hospitals have inadequate resources and are thereby unable to provide access to healthcare provisions for every citizen, especially to those in weaker economic sections.

Brazil entered a period of recession in 2015. The economy contracted by 3.6% in 2016. This was due to a fall in commodity prices and political instability that led to a decline in investor confidence. This was augmented by the Chinese economic slowdown, which led to reduced demand for commodities and the corruption scandals involving government officials and major companies. In August 2016, following mass nationwide protests, President Rousseff was impeached on charges of breaking budgetary laws and the incumbent vice president Michel Temer took over.

The report “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Brazil” an overview of the pharmaceutical and medical device market of Brazil, including the market size; market segmentation by generic, Over-The-Counter (OTC), biologic and biosimilar products; and the key drivers and barriers for the market.

In depth, this report provides the following analysis –

  • Covers the country’s reimbursement and payer landscape, as well as the regulatory landscape. The reimbursement and payer landscape section elaborates on the features of the healthcare reimbursement process for Brazil.
  • Provides a detailed analysis of the political and economic environment of Brazil. It analyzes its economic indicators, demographics, healthcare infrastructure and healthcare expenditure.
  • Provides an overview of the opportunities and challenges for growth that exist in the healthcare market of Brazil.

Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in Brazil, and includes –

  • An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers
  • Profiles and SWOT analyses of the major players in the pharmaceutical market: Pfizer, Hypermarcas, Roche, Novartis and Sanofi and Profiles and SWOT analyses of the major players in the medical device market: Johnson & Johnson, B.Braun, Medtronic, Baxter and GSK.
  • An insightful review of the reimbursement and regulatory landscape, with analysis covering details of the country’s healthcare reimbursement process, regulatory agencies and the approval processes for new drugs and medical devices
  • Detailed analysis of the country’s political and economic environment, covering economic indicators, demographics, healthcare infrastructure and healthcare expenditure
  • An overview of the opportunities for and challenges to growth in the Brazil healthcare market

Reasons to buy

This report will enhance your decision-making capability by allowing you to –

  • Develop business strategies by understanding the trends shaping and driving Brazil’s healthcare market
  • Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments and companies likely to impact Brazil’s healthcare market in the future
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing competitors’ performance
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment and strategic partnership
Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
Publisher : GlobalData
More Reports
Title Price Buy Now

Hepatitis B: Competitive Landscape to 2027

Hepatitis B: Competitive Landscape to 2027 Summary Hepatitis B is a viral infection of the liver that can become chronic in young children, especially newborns to mothers with HBV infections, and people with compromised immune systems. Chronic hepatitis B is defined as measurable Hepatitis surface antigen (HBsAg) levels for more than six months after an acute infection. Despite the existence of prophylactic vaccines, hepatitis B remains a global public health threat, with approximately 257 million people worldwide living with chronic HBV infections. Chronic hepatitis B cannot be cured and patients have elevated risks of developing liver cirrhosis and hepatocellular carcinoma (HCC). This report provides an assessment of the pipeline, clinical, and commercial landscape of Hepatitis B. Ov......
$3495

Pediatric Vaccines: Epidemiology Forecast to 2028

Pediatric Vaccines: Epidemiology Forecast to 2028 Summary The administration of a vaccine, referred to as vaccination, elicits an immune response that prevents an individual from developing a specific disease when exposed to the corresponding infectious agent in the future. A successful vaccination results in immunization, where the individual is deemed immune to the disease. Routine immunization programs aim to protect children at an early age, when they are the most vulnerable to disease. Prior to the discovery of vaccines, several infectious diseases claimed the lives of millions of children each year. GlobalData epidemiologists utilized comprehensive, country-specific vaccination rate data from nationally representative public health surveillance systems and databases to arrive at ......
$3995

Parkinson’s Disease and Behavioral Complications: PD Therapies Dominate First-in-Class Pipeline, with Novel Target Classes Demonstrating Potential Disease-Modifying Effects

Parkinson's Disease and Behavioral Complications: PD Therapies Dominate First-in-Class Pipeline, with Novel Target Classes Demonstrating Potential Disease-Modifying Effects Summary Parkinson's disease (PD), a progressive neurological disorder that affects movement control, is associated with considerable quality of life impairments and burden of care, particularly in the advanced disease stages. Cognitive and behavioral complications of PD are common. PD-associated dementia and PD-associated psychosis are both highly prevalent and associated with a large disease burden. There is a pressing unmet need within PD, PD-associated dementia, and PD-associated psychosis for more effective disease-modifying pharmacotherapies. Although current therapies can provide patients with symptomatic relie......
$6995

Obesity: Gut Hormone Receptors Retain Commercial Prominence

Obesity: Gut Hormone Receptors Retain Commercial Prominence Summary Obesity is a chronic and potentially fatal disease. The most prevalent metabolic disorder affecting people today, obesity requires multidisciplinary continuing treatment. Despite the market's clinical and regulatory challenges, the obesity pipeline is robust and contains a high level of diversity in both molecule types and molecular targets, which is in line with its multifactorial etiology. The primary concern within the market is the need for medications that adequately address the unmet clinical needs in the overweight and obese population, namely efficacious and safe therapies. This report assesses first-in-class innovation across the obesity pipeline. Scope - The obesity pipeline is robust and contains a high leve......
$6995

Colonic Diverticulitis Global Clinical Trials Review, H1, 2019

Colonic Diverticulitis Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Colonic Diverticulitis Global Clinical Trials Review, H1, 2019" provides an overview of Colonic Diverticulitis clinical trials scenario. This report provides top line data relating to the clinical trials on Colonic Diverticulitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrac......
$2500

Chronic Heart Failure Global Clinical Trials Review, H1, 2019

Chronic Heart Failure Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Chronic Heart Failure Global Clinical Trials Review, H1, 2019" provides an overview of Chronic Heart Failure clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Heart Failure. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Cl......
$2500

Contact Dermatitis Global Clinical Trials Review, H1, 2019

Contact Dermatitis Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Contact Dermatitis Global Clinical Trials Review, H1, 2019" provides an overview of Contact Dermatitis clinical trials scenario. This report provides top line data relating to the clinical trials on Contact Dermatitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trial......
$2500

Cirrhosis Global Clinical Trials Review, H1, 2019

Cirrhosis Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Cirrhosis Global Clinical Trials Review, H1, 2019" provides an overview of Cirrhosis clinical trials scenario. This report provides top line data relating to the clinical trials on Cirrhosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are coll......
$2500

Cutaneous T-Cell Lymphoma Global Clinical Trials Review, H1, 2019

Cutaneous T-Cell Lymphoma Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Cutaneous T-Cell Lymphoma Global Clinical Trials Review, H1, 2019" provides an overview of Cutaneous T-Cell Lymphoma clinical trials scenario. This report provides top line data relating to the clinical trials on Cutaneous T-Cell Lymphoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - ......
$2500

Community Acquired Pneumonia Global Clinical Trials Review, H1, 2019

Community Acquired Pneumonia Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Community Acquired Pneumonia Global Clinical Trials Review, H1, 2019" provides an overview of Community Acquired Pneumonia clinical trials scenario. This report provides top line data relating to the clinical trials on Community Acquired Pneumonia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy